Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study.

Lapatinib-induced skin adverse events predict better outcomes in canine urothelial carcinoma.

This retrospective cohort study examined dermatological adverse events (DAEs) in 85 dogs with urothelial carcinoma treated with lapatinib and piroxicam compared to 42 dogs receiving piroxicam alone. DAEs occurred in 31.8% of the lapatinib/piroxicam group versus 7.1% in the piroxicam-only group, with alopecia and hyperpigmentation being most prevalent. The relative risk of developing DAEs was 4.4 times higher in the combination therapy group. Notably, dogs experiencing DAEs demonstrated significantly longer progression-free survival (PFS), with Cox proportional hazards analysis confirming DAEs as an independent positive prognostic factor (hazard ratio 0.52). These findings suggest that dermatological adverse events, commonly observed with lapatinib therapy in both human and veterinary oncology, may serve as biomarkers of treatment efficacy in canine urothelial carcinoma. The study supports the clinical use of lapatinib/piroxicam combination therapy while establishing that cutaneous manifestations correlate with improved therapeutic outcomes.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.